0

Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

Repligen Initiates Phase 2 Clinical Trial Of RG2417 For Bipolar Depression

  • 작성자한진
  • 작성일2006-03-15 00:23:32
  • 조회수16093
  • 첨부파일첨부파일
This Article Also Appears In Clinical Trials Main Category: Bipolar News Article Date: 10 Mar 2006 - 3:00am (UK) Repligen Corporation (Nasdaq: RGEN) today announced that the Company has initiated a Phase 2 clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This Phase 2 study is a multi-center, dose escalating study in which 80 patients will receive either RG2417 or a placebo for 6 weeks. Patients will be evaluated for the safety and effectiveness of RG2417 on the symptoms of bipolar depression. This study is being conducted under a development agreement with the Stanley Medical Research Institute, under which Repligen will receive approximately $1,000,000 in funding. The Stanley Medical Research Institute is the largest nonprofit provider of funding for research on schizophrenia and bipolar disorder in the United States. "Bipolar depression is a serious chronic illness and treatment is challenging due to the potential for induction of mania, a common side effect of standard treatment with antidepressants," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen. "If this proof of principle study shows evidence that RG2417 improves the symptoms of bipolar depression without inducing mania, it has the potential to be an important new therapy in an area of significant unmet medical need." Repligen previously completed a 6-week Phase 1 clinical trial of a prodrug of uridine (RG2133) in patients with bipolar disorder or major depression. The results demonstrated that administration of RG2133 in this patient population appeared to be safe, did not induce mania, and provided early evidence of a clinical effect of the drug. The trial evaluated 19 patients and was carried out by investigators at McLean Hospital, the largest psychiatric clinical care, teaching and research affiliate of Harvard Medical School. Uridine is a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential for cell metabolism. Uridine is synthesized by the power plant of the human cell known as the mitochondria. The rationale for uridine therapy in neuropsychiatric disorders is supported by pre-clinical and clinical research. Researchers at McLean Hospital previously demonstrated that uridine is active in a well-validated animal model of depression. Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down-regulated in the brains of bipolar patients. This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain. About Bipolar Disorder Bipolar disorder, also known as manic depression, is an illness marked by extreme changes in mood, thought, energy and behavior in which a person's mood can alternate between the "poles" of mania (highs) and depression (lows). Bipolar disorder affects more than two million adults in the United States and is usually diagnosed in late adolescence or early adulthood. Bipolar disorder is a chronic illness associated with substantial morbidity and mortality, ranking worldwide behind only unipolar depression and alcohol abuse among psychiatric illnesses for related disabilities and overall economic burden of illness. The lifetime financial burden of bipolar disorder in the United States is about $625,000 per patient, depending on resistance to treatment and persistence of symptoms. Although lithium and anticonvulsants such as valproic acid have substantially improved the prognosis of bipolar disorder, many individuals are unable to tolerate treatment-related side effects, and incomplete clinical response, relapse, and recurrence remain common clinical problems. About The Stanley Medical Research Institute The Stanley Medical Research Institute (SMRI) is a nonprofit organization that supports research on the causes and treatment of schizophrenia and bipolar disorder (manic-depressive illness), both through work carried out in its own laboratories and through support of researchers worldwide who are working on these diseases. SMRI is the largest nonprofit provider of research funding for schizophrenia and bipolar disorder in the United States and has provided over $200 million in funding since 1999. SMRI funds approximately half of all U.S. research on bipolar disorder and approximately one quarter of the research on schizophrenia. Schizophrenia and bipolar disorder are the major psychiatric disorders in the United States, affecting more than 4 million people. About Repligen Corporation Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of novel therapeutics for profound neuropsychiatric disorders and autoimmune disease. Repligen has a Specialty Pharmaceuticals business comprised of rProtein A(TM) and SecreFlo(R), the profits from which will be used to partially support the development of our proprietary products. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com. This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein. Repligen Corporation http://www.repligen.com
Total406 [ page9/28 ]
No. 제목 작성자 작성일 조회수
286 '레스베라트롤(resveratrol)이 미토콘드리아 기능을 억제하여 암세포를 죽인다. 2008.03.26 한진 2008.03.26 3,619
285 비만치료의 새 표적: 미토콘드리아 언커플링 (2008-03-16) 2008.03.19 한진 2008.03.19 2,898
284 완전 축하 합니다 박원선 선생 둘째 아들 탄생!! 2008.02.13 김형규 2008.02.13 2,476
283 한번더 축하 드립니다 고재홍 선생님!!! 2008.01.31 강성현 2008.01.31 2,423
282 "2008년 한국생화학분자생물학회 정기 학술대회 및 대한생화학분자생물학회 통합심포지엄" 2008.01.31 한진 2008.01.31 3,000
281 연세의대 2008.01.31 한진 2008.01.31 2,434
280 칼자이스 유저 스토리 2008.01.25 한진 2008.01.25 2,270
279 아시아 미토콘드리아 의학 연구회 2008.01.14 박원선 2008.01.14 2,656
278 Coming soon, an anti-ageing injection 2007.08.19 한진 2007.08.19 2,536
277 Thanks and Good-bye from Khoa. 2007.06.28 트란민콰 2007.06.28 2,622
276 Flavored Oxygen Rocks World of Energy Drinks and Supplements 첨부파일 2007.06.25 한진 2007.06.25 3,101
275 Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau 첨부파일 2007.06.25 한진 2007.06.25 3,084
274 Researchers identify protein pathway involved in Parkinson disease development 첨부파일 2007.06.25 한진 2007.06.25 2,530
273 I introduced our lab to people in Auckland. 첨부파일 2007.06.13 김나리 2007.06.13 2,311
272 New technique may be used with confocal microscope 첨부파일 2007.05.31 Dang Van Cuong 2007.05.31 2,052
처음이전 1 2 3 4 5 6 7 8 9 10 다음 마지막